دورية
Motixafortide Enables Consistent, Robust Hematopoietic Stem Cell Collection (HSC) across Populations with Increased Impaired HSC Mobilization: A Sub-Group Analysis of the Genesis Study
| العنوان: | Motixafortide Enables Consistent, Robust Hematopoietic Stem Cell Collection (HSC) across Populations with Increased Impaired HSC Mobilization: A Sub-Group Analysis of the Genesis Study |
|---|---|
| المؤلفون: | Crees, Zachary D, Rettig, Michael P., Jayasinghe, Reyka, Stockerl-Goldstein, Keith, Larson, Sarah M, Arpad, Illes, Milone, Giuseppe, Martino, Massimo, Stiff, Patrick J., Sborov, Douglas, Pereira, Denise, Micallef, Ivana N, Moreno-Jiménez, Gemma, Mikala, Gabor, Coronel, Maria L Paciello, Holtick, Udo, Hiemenz, John, Qazilbash, Muzaffar H., Hardy, Dr. Nancy Maureen, Latif, Tahir, Garcia-Cadenas, Irene, Vainstein-Haras, Abi, Sorani, Ella, Gliko-Kabir, Irit, Goldstein, Inbal, Ickowicz, Debby, Darvish, Liron, Kadosh, Shaul, Gao, Feng, Schroeder, Mark A., Vij, Ravi, DiPersio, John F. |
| المصدر: | Transplantation and Cellular Therapy; February 2024, Vol. 30 Issue: 2, Number 2 Supplement 1 pS390-S391, 2p |
| مستخلص: | The clinical benefit of autologous hematopoietic stem cell transplant (ASCT) for multiple myeloma (MM) partly depends on the ability to collect sufficient hematopoietic stem cells (HSCs) from peripheral blood (PB). Risk factors for impaired HSC mobilization are increasingly common in patients with MM undergoing ASCT in the current treatment landscape, including advanced age, presence of cytopenias and prior exposure to radiation, lenalidomide and/or anti-CD38 monoclonal antibodies (mAb). Motixafortide is a novel high affinity CXCR4 antagonist indicated, in combination with G-CSF, for mobilization of HSCs to the PB for collection and subsequent ASCT in MM. In the GENESIS trial (NCT03246529), a single dose of motixafortide, in combination with G-CSF, enabled a significantly greater proportion of subjects to mobilize ≥6 × 106CD34+ cells/kg in up to 2 aphereses. Here we report the results of subgroup analyses of the GENESIS trial evaluating baseline characteristics and risk factors for impaired mobilization. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 26666375 26666367 |
|---|---|
| DOI: | 10.1016/j.jtct.2023.12.548 |